| Bioactivity | BML-260 is a potent inhibitor of dual-specific phosphatases JSP-1 and DUSP22. BML-260 can activate UCP1 and thermogenesis in adipocytes in a JSP-1-independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB, STAT3, and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity[1][2]. |
| CAS | 101439-76-3 |
| Formula | C17H11NO3S2 |
| Molar Mass | 341.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Williams D R, et al. Targeting phosphatase DUSP22 ameliorates skeletal muscle wasting via Akt independent JNK-FOXO3a repression[J]. bioRxiv, 2024: 2024.04. 08.588643. [2]. Feng Z, et al. Identification of a rhodanine derivative BML-260 as a potent stimulator of UCP1 expression[J]. Theranostics, 2019, 9(12): 3501. |